Related Experiment Video

Updated: Jul 3, 2026

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
12:41

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat

Published on: August 28, 2021

Dexmedetomidine disposition in children: a population analysis

Amanda L Potts1, Guy R Warman, Brian J Anderson

  • 1University of Auckland, Auckland, New Zealand. a.potts@auckland.ac.nz

Paediatric Anaesthesia
|July 11, 2008
PubMed

Insights

Pediatric dexmedetomidine pharmacokinetics (PK) show immature clearance in neonates, requiring dose adjustments. Dosing should be reduced in infants for safe sedation and arousal, based on population PK analysis.

Area of Science:

  • Pharmacology
  • Pediatric Anesthesiology
  • Clinical Pharmacy

Background:

  • Limited pharmacokinetic data exist for dexmedetomidine in children (0-15 years).
  • Increasing use of dexmedetomidine in pediatric populations necessitates PK understanding.

Purpose of the Study:

  • To characterize the population pharmacokinetics (PK) of intravenous dexmedetomidine in children post-cardiac surgery.
  • To establish PK parameters and understand age-related maturation of drug clearance.

Main Methods:

  • An open-label study involving 45 children receiving i.v. dexmedetomidine.
  • Population PK analysis using nonlinear mixed effects modeling on 148 concentration-time profiles.
  • Allometric scaling used to standardize PK estimates to a 70-kg adult.

Main Results:

  • A two-compartment model best described dexmedetomidine disposition.
  • Population PK parameter estimates (CL, V1, Q, V2) were determined.
  • Clearance at birth was ~1/3 of adult values, maturing to 87% of adult rate by 1 year.

Conclusions:

  • Neonatal dexmedetomidine clearance is significantly lower than in adults due to immature pathways.
  • Reduced maintenance dosing is recommended for neonates and infants when using target concentration strategies.
  • Understanding pediatric PK is crucial for optimizing dexmedetomidine therapy.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...